Akebia Therapeutics | AKBA - 流动负债



金融业
股票价格
USD
资产
USD 362.52M
现金及等价物
USD 162.64M
销售成本
USD 10.34M
流动资产
USD 243.48M
流动负债
USD 173.88M
债务
USD 46.51M
股息收益率
0
EBIT
USD -5.45M
EBITDA
USD 14.03M
员工
167
EPS每股收益
USD -0.04
股本和储备
USD 27.38M
销售毛利
USD 47.28M
债务利息支出
362.52M
贷款资金
USD 36.4M
市值
USD 216.7M
净收入
USD -12.24M
营业费用
USD 63.08M
营业利润
USD -5.45M
普通股股本
USD 265.43M
PE价格收益
1.63K
税前利润
USD -11.24M
销售收入
USD 57.62M
销售和管理费用
USD 23.53M
股票
USD 13M
贸易债权人
USD 8.39M
应收帐款人
USD 47.03M


流动负债 更改 日
Acadia Pharmaceuticals USD 305.52M 28.41M 2026-03
Agios Pharmaceuticals USD 58.84M 23.36M 2026-03
Akebia Therapeutics USD 173.88M 10.95M 2026-03
Alnylam Pharmaceuticals USD 1.35B 116.87M 2026-03
Amgen USD 24.96B 534M 2026-03
Ardelyx USD 109.57M 20.96M 2026-03
Astellas Pharma JPY 1.22T 106.19B 2026-03
AstraZeneca USD 32.57B 1.95B 2026-03
Bayer EUR 33.46B 875M 2026-03
BioMarin Pharmaceutical USD 793.15M 34.12M 2026-03
Celltrion KRW 283.62B 3.72T 2025-12
Cspc Pharmaceutical CNY 10.18B 65.36M 2025-12
Deva Holding AS TRY 6.43B 1.18B 2023-09
Dianthus Therapeutics USD 38.28M 7.55M 2026-03
Exelixis USD 370.98M 34.67M 2026-03
Fresenius Medical Care EUR 6.73B 484.42M 2026-03
GlaxoSmithKline GBP 22.43B 1.04B 2026-03
Ionis Pharmaceuticals USD 717M 66M 2026-03
Ironwood Pharmaceuticals USD 236.31M 5.91M 2026-03
J&J USD 57.72B 3.59B 2026-03
Kangmei Pharma CNY 5.81B 57.93M 2025-09
Karyopharm Therapeutics USD 92.06M 4.9M 2025-12
Knight Therapeutics CAD 165.26M 12.58M 2025-12
Laboratorios Farma EUR 199.84M 121.75M 2023-12
Lexicon Pharmaceuticals USD 9.9M 10.97M 2026-03
Malin Corporation EUR 1000K 500K 2024-12
Medical Developments International AUD 5.56M 2.26M 2025-12
Moderna USD 2.4B 408M 2026-03
Nektar Therapeutics USD 53.54M 12.8M 2025-12
Neuren Pharmaceuticals AUD 4.34M 3.58M 2025-12
Organigram Holdings CAD 94.05M 32.11M 2025-12
Ovoca Bio EUR 186K 2.26M 2025-06
Pharma Mar EUR 89.23M 4.65M 2026-03
Prothena USD 32.52M 8.33M 2026-03
PTC Therapeutics USD 923.6M 44.82M 2026-03
Qiagen NV USD 512.14M 461.26M 2025-12
Regeneron Pharmaceuticals USD 5.11B 739.3M 2026-03
Roche Holding CHF 28B 421M 2025-12
Sanofi EUR 30.01B 1.66B 2026-03
Sarepta Therapeutics USD 499.16M 596.13M 2026-03
Sartorius EUR 2.11B 145.8M 2026-03
Sino Biopharmaceutical CNY 24.85B 5.29B 2025-06
Tectonic Therapeutic USD 12.96M 3.29M 2026-03
Tilray USD 259.32M 8.32M 2025-09
Vanda Pharmaceuticals USD 145.16M 27.29M 2025-12
Zealand Pharma A/S 664.96M 513.61M 2025-12
Zz Pientze Pharmaceu CNY 2.28B 134.52M 2026-03